You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The COPD and asthma space is an exciting potential area of growth for AstraZeneca -- but is it enough?
One of the main things that AstraZeneca's (AZN 0.19%) management highlighted in making the case against Pfizer's proposed acquisition of the British pharma was the large and diverse drug pipeline.
In the video below, health care analysts Michael Douglass and David Williamson discuss a key part of Astra's case -- its respiratory drug portfolio and pipeline.
David Williamson owns shares of Pfizer. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
